Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for treating a mammal before, during and after cardiac arrest

A technology for mammals, cardiac arrest, applied in mammals during and after, to treat the field before cardiac arrest, which can solve problems such as affecting the blood flow of organs, damage to cardiac function, and long duration of vasoconstriction effect.

Inactive Publication Date: 2007-09-05
ABBOTT LAB INC
View PDF8 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, beta-receptor antagonists are negative inotropes that can lead to impairment of cardiac function during and after resuscitation
In addition, vasopressin treats cardiac arrest by improving coronary perfusion pressure without negative effects on beta-receptor agonism
However, during the postresuscitation period, the vasopressin effects of vasopressin are longer lasting and affect organ blood flow

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating a mammal before, during and after cardiac arrest
  • Methods for treating a mammal before, during and after cardiac arrest
  • Methods for treating a mammal before, during and after cardiac arrest

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0089] Embodiment 1: Levosimendan is used for the treatment of suffering from post-cardiac arrest resuscitation

[0090] Uses for myocardial dysfunction in mammals

[0091] All animals received humane care and guidelines for the care and use of laboratory animals in accordance with the Principles of Laboratory Animal Care formulated by the National Society for Research in Medicine, which were issued by the Prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication 86-32, revised 1985).

[0092]Method: Male Sprague-Dawley rats weighing 500-550 g were fasted overnight and allowed to drink water freely. Animals were anesthetized by intraperitoneal injection of pentobarbital (45 mg / kg). Additional doses (10 mg / kg) were administered approximately every hour, or as needed to maintain anesthesia, in addition, non-anesthetics were administered 30 minutes prior to induction of cardiac arrest. Acc...

Embodiment 2

[0100] Example 2: Dobutamine and Levosimendan

[0101] Comparison in Treatment of Rats with Postresuscitated Myocardial Failure

[0102] Dobutamine is widely used in the treatment of myocardial systolic failure after resuscitation from prolonged cardiac arrest. However, dobutamine has the potential to increase the severity of ischemic myocardial injury. Levosimendan, an additional inotrope, has the benefit of improving myocardial contractility without increasing the severity of ischemic injury. Therefore, an experiment was performed to determine whether administration of levosimendan, when resuscitated from cardiac arrest, reduces postresuscitated myocardial ischemic injury and improves outcome compared with dobutamine and placebo.

[0103] Animal preparation: Fifteen male Sprague-Dawley rats weighing 450 and 550 g were fasted overnight with free access to water. Subsequent intraperitoneal injection of 45 mg kg -1 pentobarbital to anesthetize...

Embodiment 3

[0114] Example 3: Dobutamine and levosimendan for treatment

[0115] Comparison in Postresuscitated Myocardial Failure in Rats

[0116] Experimental preparation: This experiment was carried out in the commonly used pig model of cardiac arrest and cardiac resuscitation. (21, 22). Briefly, 15 male domesticated pigs weighing 35 and 40 kg were fasted overnight with free access to water. Intramuscular injection of ketamine (anesthetic) (20mg / kg -1 ) to start anesthesia, ear intravenous injection of sodium pentobarbital (30mg / kg -1 ) to complete the anesthesia. Anesthesia was maintained by injecting additional doses of sodium pentobarbital (8 mg / kg) every hour. A cuffed endotracheal tube is inserted into the trachea. Mechanically ventilate the animal 15 mL kg with the aid of a volume-controlled ventilation device (Model MA-1, Puritan-Bennett, Carlsbad, CA) -1 , the maximum airflow is 40L min -1 , FiO 2 is 0.2. End-tidal PCO was detected with an infrared analyzer (Model 01R...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods for treating mammals before, during and after cardiac arrest are disclosed. Pharmaceutical compositions comprising levosimendan useful for such treatment also are disclosed.

Description

technical field [0001] The present invention relates to methods for treating mammals before, during and after cardiac arrest, and pharmaceutical compositions suitable for use in said methods. Background technique [0002] Cardiovascular disease remains the leading cause of death in the Western world. When a person suffers from cardiac arrest, whether in the hospital or elsewhere, the survival rate is quite low. Furthermore, although the initial cure rate of cardiopulmonary resuscitation is about 39% (13 to 59%), most of these victims die within 72 hours, mainly from heart failure and / or recurrent ventricular fibrillation. Sadly, only 5% or 1 in 8 of successfully resuscitated discharged patients survive after hospitalization. In experimental models (Tang et al., Crit. Care Med., 21: 1046-1050 (1993); Tang et al., Circulation, 92: 3089-3093 (1995); Gazmuri et al., Crit. Care Med., 24 : 992-1000 (1996); Kern et al. J. Am. Coll. Cardiol, 28: 232-240 (1996)) and in human patie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/50A61P9/04A61N1/39
CPCA61N1/39A61K31/50A61K31/122A61N1/39044A61P1/16A61P13/12A61P25/00A61P43/00A61P9/00A61P9/04A61P9/06A61P9/10
Inventor M·H·威尔S·孙W·唐L·德尔加多-埃雷拉R·J·帕利
Owner ABBOTT LAB INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com